OncLive® On Air

Anne Chiang, MD, PhD, a Yale oncologist and translational investigator in small cell lung cancer, discusses the evolving treatment landscape. She highlights shifts since chemoimmunotherapy, disease heterogeneity and biomarker-driven trials. Chiang explores DLL3-targeted therapies like tarlatamab and practical considerations for tailoring therapy and trial access.

In today’s episode, we sat down with Megan Kruse, MD; and Sophia O’Brien, MD. Dr Kruse is a breast medical oncologist at Cleveland Clinic in Ohio. Dr O’Brien is an assistant professor of clinical radiology in the Divisions of Nuclear Medicine and Breast Imaging, as well as the associate program director of the Diagnostic Radiology Residency, at Penn Medicine in Philadelphia, Pennsylvania.In our exclusive interview, Drs Kruse and O’Brien highlighted the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making, noting the unique role of 18F-fluoroestradiol (FES)–PET/CT in lobular breast cancer, how future evolutions of breast imaging may influence FES-PET/CT use, and the importance of strong collaborations between medical oncologists and nuclear medicine physicians.

In this podcast, experts Marwan Fakih, MD, Kristen Ciombor, MD, MSCI, and Van Karlyle Morris, MD, discuss the treatment of advanced squamous cell anal carcinoma in the immunotherapy era, with a focus on epidemiology, frontline treatment, and novel approaches to immunotherapy-refractory disease.

David Carbone, MD, PhD, a thoracic oncology leader at Ohio State, discusses six-year CheckMate 9LA results. He highlights durable survival with nivolumab plus ipilimumab and chemo. Strong outcomes appear in PD-L1–negative and squamous tumors. He also talks about biomarker limits, toxicity management, and practical treatment sequencing for community clinicians.

Sarah Sammons, MD, an associate director at Dana-Farber and Harvard faculty, outlines pumitamig, a bispecific PD-L1/VEGF-A antibody. She explains the drug’s mechanism and rationale. She reviews phase 2 trial design, strong response rates, safety signals, and plans for a phase 3 registrational study. She also places pumitamig among emerging immunotherapy and ADC strategies for triple-negative breast cancer.

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.Chugh is a clinical professor and service chief of Internal Medicine at the University of Michigan Medical School, as well as an oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor.In the exclusive interview, Dr Chugh expanded on the current unmet needs and treatment goals in desmoid tumors, the biologic rationale for γ-secretase inhibition and emerging biomarker considerations, and the potential clinical role of varegacestat based on positive topline data from the phase 2/3 RINGSIDE trial (NCT04871282).Of note, submission of a new drug application to the FDA for this agent in progressing desmoid tumors is planned for the second quarter of 2026._____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

John V. Heymach, MD, PhD, a thoracic oncology physician-scientist, and Anne S. Tsao, MD, MBA, a medical oncologist focused on thoracic immunotherapy, discuss bispecific antibodies. They cover PD-1/CTLA-4 platforms, VEGF–PD-1 mechanisms and trial data, and DLL3-directed T-cell engagers like tarlatimab. Conversation also touches on safety management and potential roles in thoracic cancers.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Susana M. Campos, MD, MPH. Dr Campos is the clinical director and director of Educational Initiatives for the of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an institute physician and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Drs Matulonis and Campos discussed the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.According to 2026 estimates from the American Cancer Society, approximately 13,400 new cases of invasive cervical cancer will be diagnosed in the United States, with roughly 4200 deaths. Although incidence has declined over time due to human papillomavirus (HPV) vaccination and screening efforts, rates have plateaued, and the disease burden remains substantial, particularly among women aged 35 to 64 years. Dr Campos noted that approximately half of cases occur in women younger than 50 years of age, and about 20% are diagnosed in women older than 65 years of age.Dr Campos reviewed common presenting symptoms, including abnormal vaginal bleeding, intermenstrual or postmenopausal bleeding, abnormal discharge, pelvic pain, and, in advanced cases, urinary symptoms or leg swelling. She explained that diagnosis begins with pelvic examination and cervical cytology or HPV testing, followed by colposcopy and biopsy when indicated. Although cervical cancer remains one of the few malignancies that is clinically staged, imaging modalities, such as MRI, CT, and PET scans, are critical to accurately defining disease extent, they underscored. Moreover, the discussion highlighted transformative advances in locally advanced disease. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated improved progression-free and overall survival with the addition of pembrolizumab (Keytruda) to standard chemoradiation, establishing a new standard for high-risk patients, Campos stated. Similarly, the phase 3 INTERLACE trial (NCT01566240) showed that short-course induction chemotherapy with carboplatin and paclitaxel before chemoradiation improved long-term outcomes. Campos forecasted that ongoing studies, including the phase 3 NRG-GY037 trial (NCT07061977), may integrate these approaches and further refine optimal treatment sequencing.Lastly, Drs Matulonis and Campos highlighted the expanding therapeutic arsenal in the recurrent and metastatic setting. Campos noted how antibody-drug conjugates, such as tisotumab vedotin-tftv (Tivdak) and fam-trastuzumab deruxtecan-nxki (Enhertu), have demonstrated meaningful activity, particularly in biomarker-selected populations. Campos added that investigational strategies targeting TROP2, such as sacituzumab govitecan-hziy (Trodelvy), represent additional promising avenues.Despite these advances, both experts emphasized that prevention remains paramount. Widespread uptake of HPV vaccination, including the 9-valent vaccine, as well as adherence to routine cervical screening, are essential to reducing the long-term burden of this largely preventable disease.

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, sat down with OncLive to discuss treatment goals and other patient factors weighed when navigating first-line chemotherapy selection in metastatic pancreatic cancer.Shroff is the associate director of clinical investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Comprehensive Cancer Center in Tucson. She also is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology for the University of Arizona College of Medicine – Tucson, and medical director for the Oncology Service Line with Banner Health. Spencer is a medical oncologist and director of the Phase 1 Program at the New York University Langone Perlmutter Cancer Center.In the exclusive interview, Drs Shroff and Spencer discuss the evolving role of NALIRIFOX within the frontline treatment paradigm; the decision between standard first-line chemotherapy and clinical trial enrollment for patients with metastatic pancreatic cancer; and the importance of mentorship and leadership development for women in the field of gastrointestinal oncology._____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today’s episode, we welcomed Quinto Gesiotto, MD, a malignant hematologist at Tampa General Hospital in Florida.In the exclusive interview, Dr Gesiotto explored the evolving role of TKIs in the treatment of patients with chronic myeloid leukemia (CML), including dosing patterns for ponatinib (Iclusig) in those with CML and other TKI data to emerge in the CML space at the 2025 ASH Annual Meeting and Exposition. Dr Gesiotto also provided detail on emerging data on novel strategies and agents, along with genetic mutations beyond BCR-ABL1 T315I the could drive more personalized treatment sequencing and improved risk stratification in CML in the future.